UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

GENE COMPANY PTY LTD,
Petitioner,

v.

THE TRUSTEES OF COLUMBIA UNIVERSITY
IN THE CITY OF NEW YORK,

Patent Owner.

Case No. IPR2024-00313
U.S. Patent No. RE47,045

PATENT OWNER'S UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner The Trustees of Columbia University in the City of New York hereby submits a current listing of Patent Owner exhibits. Exhibits 2040-2045, 2047-2050 are being served today.

Exhibit	Description	Served Not Filed
2001	Guangwen Tang et al., *Deuterium enrichment of retinol in humans determined by gas chromatography electron capture negative chemical ionization mass spectrometry*, 9 J. Nutr. Biochem. 408-14 (1998)	
2002	J.A. Pardoen et al., *Synthesis of retinals isotopically labelled at positions 11, 12, 14 and 20*, 105 Recl. Trav. Chim. Pays-Bas 92-98 (1986)	
2003	Gabriel H. Travis et al., *Diseases Caused by Defects in the Visual Cycle: Retinoids as Potential Therapeutic Agents*, *published in final edited form in* 47 Annu Rev Pharmacol Toxicol 469-512 (2007)	
2004	WO 2005/065669 A1 (Lang)	
2005	U.S. Patent Application Pub. No. 2007/0015827 A1 (Widder 2007)	
2006	Yardana Kaufman et al., *Deuterium Enrichment of Vitamin A at the C20 Position Slows the Formation of Detrimental Vitamin A Dimers in Wild-type Rodents*, 286 J. of Biological Chem. 7958-65 (2011)	
2007	Allan B. Foster, *Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design*, 14 Advances in Drug Research 1-40 (1985)	

Exhibit	Description	Served Not Filed
2008	Declaration of F. Peter Guengerich Ph.D. in Support of Petition for *Inter Partes* Review of Claims 1-15 of U.S. Patent No. 9,249,149, *Incyte Corp. v. Concert Pharmaceuticals, Inc.*, IPR2017-01256, Ex. 1002 (PTAB Apr. 7, 2017)	
2009	Videotaped Deposition of F. Peter Guengerich, Ph.D., *Incyte Corp. v. Concert Pharmaceuticals, Inc.*, IPR2017-01256, Ex. 2047 (PTAB Jun. 23, 2018)	
2010	Videoconference Deposition of Peter Guengerich, Ph.D., *Alzheon, Inc. v. Risen (Suzhou) Pharma Tech Co., Ltd.*, IPR2021-00347, Ex. 2041 (PTAB Sept. 28, 2021)	
2011	U.S. Patent Application Pub. No. 2006/0135460 A1 (Widder 2006)	
2012	U.S. Patent No. 7,973,079 (Mata 2011)	
2013	U.S. Patent Application Pub. No. 2012/0202885 A1 (Widder 2012)	
2014	Di Huang et al., *Stargardt disease and progress in therapeutic strategies*, 43(1) Ophthalmic Genetics 1-26 (2022)	
2015	Rehan M. Hussain et al., *Stargardt macular dystrophy and evolving therapies*, *published in final edited form in* 18(10) Expert Opinion on Biological Therapy 1049-59 (2018)	
2016	Jana Zernant, ABCA4 *as a Model for Complex Genetics in Monogenic Diseases*, Tallinn University of Technology Doctoral Thesis (2019)	
2017	Thomas A. Ciulla, *Seeking Therapies for Stargardt Macular Dystrophy*: *Clinical research teams are working toward a treatment for Stargardt disease. How far have they come?*, Retina Today 26-30 (July/August 2019)	

Exhibit	Description	Served Not Filed
2018	Robert Thornton Morrison & Robert Neilson Boyd, *Organic Chemistry* 858-59 (3d ed. 1973)	
2019	So R. Kim et al., *Characterization of dihydro-A2PE: an Intermediate in the A2E Biosynthetic Pathway*, *published in final edited form in* 46(35) Biochemistry 10122-29 (2007)	
2020	Nicolas J. Saettel & Olaf Wiest, *Ab Initio Studies of [1,5]-H Shifts: Pentadiene and Beyond*, 65(8) J. Org. Chem. 2331-36 (2000)	
2021	Kersey A. Black et al., *Alkynes, Allenes, and Alkenes in [3,3]-Sigmatropy: Functional Diversity and Kinetic Monotony. A Theoretical Analysis*, 120 J. Am. Chem. Soc. 5622-27 (1998)	
2022	Kenneth A. Connors, *Chemical Kinetics: The Study of Reaction Rates in Solution*, 1-15, 187-243 (1990)	
2023	Omitted	
2024	Rory A. More O'Ferrall, *Substrate Isotope Effects*, Proton-Transfer Reactions 201-61 (Edward Caldin & Victor Gold eds., 1975)	
2025	William von E. Doering & Xin Zhao, *Effect on Kinetics by Deuterium in the 1,5-Hydrogen Shift of a Cisoid-Locked 1,3(Z)-Pentadiene, 2-Methyl-10-methylenebicyclo[4.4.0]dec-1-ene: Evidence for Tunneling?*, 128 J. Am. Chem. Soc. 9080-85 (2006)	
2026	National Institutes of Health Office of Dietary Supplements, Vitamin D Fact Sheet for Health Professionals, https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/ (Updated Sept. 18, 2023)	
2027	Charles DeBoer et al., *Oral Drug Pipeline for Retinal Disease*, 19 Retinal Physician 27-28, 20, 32 (July 1, 2022)	

Exhibit	Description	Served Not Filed
2028	Griffith News, *Griffith University and Gene Company partner to create exciting RNA-based COVID anti-viral*, https://news.griffith.edu.au/2023/07/26/griffith-university-and-gene-company-partner-to-create-exciting-rna-based-covid-anti-viral/ (July 26, 2023)	
2029	Tawain News, *Queensland treasurer visits Taiwan to further trade, business, education, cultural links*, https://www.taiwannews.com.tw/news/4979623 (Aug. 24, 2023)	
2030	John-Paul Langbroek, *Report to Queensland Parliament On a Queensland Parliamentary Delegation to Republic of China (Taiwan)* (Apr. 26-May 1, 2023) (Parliament Report 2)	
2031	Cameron Dick, *Report to Parliament: Indonesia and Taiwan Trade and Investment Mission* (Aug. 9-16, 2023)(Parliament Report)	
2032	U.S. Securities and Exchange Commission Amendment No. 2 to Form F-1 for Belite Bio, Inc. (Apr. 22, 2022)	
2033	Michael B. Smith & Jerry March, *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure* 98-105 (6th ed. 2007)	
2034	Jerry Huang LinkedIn Page, www.linkedin.com/in/jerry-huang-60a98051	
2035	Wilson Sonsini Press Release, *Firm Advises Belite Bio on IP Matters Related to $36 million IPO*, https://www.wsgr.com/en/insights/firm-advises-belite-bio-on-ip-matters-related-to-dollar36-million-ipo.html (May 3, 2022)	
2036	Declaration of Jonathan L. Sessler Ph.D.	
2037	Curriculum Vita of Jonathan L. Sessler Ph.D.	

Exhibit	Description	Served Not Filed
2038	Eric V. Anslyn & Dennis A. Dougherty, *Modern Physical Organic Chemistry* 421-41 (2006)	
2039	Gene Company Pty Ltd LinkedIn Post	
2040	So R. Kim et al., *Characterization of Dihydro-A2PE: An Intermediate in the A2E Biosynthetic Pathway*, ACS Publications, https://pubs.acs.org/doi/10.1021/bi7009635 (last visited July 18, 2024)	X
2041	Log in with your ACS ID, ACS Publications, https://pubs.acs.org/action/addToCart?id=PPVJOURNALSE-ELECTRONIC-USD-10.1021%2FBI7009635-137903 (last visited July 18, 2024)	X
2042	Order form, ACS Publications, https://pubs.acs.org/action/addToCart?id=PPVJOURNALSE-ELECTRONIC-USD-10.1021%2FBI7009635-137903 (last visited July 18, 2024)	X
2043	ACS Publications purchase confirmation email, dated July 18, 2024	X
2044	So R. Kim et al., *Characterization of Dihydro-A2PE: An Intermediate in the A2E Biosynthetic Pathway*, 46(35) Biochemistry 10122-29 (2007)	X
2045	Michael B. Smith & Jerry March, *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure* (6th ed. 2007)	X
2046	Omitted	
2047	Eric V. Anslyn & Dennis A. Dougherty, *Modern Physical Organic Chemistry* 421-88 (2006)	X

Exhibit	Description	Served Not Filed
2048	Rehan M. Hussain et al., *Stargardt macular dystrophy and evolving therapies*, *published in final edited form in* 18(10) Expert Opinion on Biological Therapy 1049-59 (2018), ScholarWorks, https://scholarworks.indianapolis.iu.edu/items/e4bfc377-999d-4940-bf07-ddf429b33b38 (last visited July 17, 2024)	X
2049	Rehan M. Hussain et al., *Stargardt macular dystrophy and evolving therapies*, *published in final edited form in* 18(10) Expert Opinion on Biological Therapy 1049-59 (2018)	X
2050	Declaration of Shauna L. Wiest	X

Respectfully submitted,

Dated: July 23, 2024

By: /Drew D. Christie/
Drew D. Christie, Reg. No. 78,004
Finnegan, Henderson, Farabow,
Garrett & Dunner, LLP

Counsel for Patent Owner
The Trustees of Columbia University in the City of New York

CERTIFICATE OF SERVICE

The undersigned certifies that a copy of the foregoing **Patent Owner's Updated Exhibit List** and **Exhibits 2040-2045, 2047-2050** were served electronically via email on July 23, 2024, in their entirety on the following:

Jad A. Mills
Michael T. Rosato
Wilson, Sonsini, Goodrich & Rosati
701 Fifth Avenue, Suite 5100
Seattle, WA 98104-7036
jmills@wsgr.com
mrosato@wsgr.com

Matthew Bresnahan
Wilson, Sonsini, Goodrich & Rosati
12235 El Camino Real
San Diego, CA 82130-3002
mbresnahan@wsgr.com

Petitioner has consented to service by electronic mail.

Dated: July 23, 2024

/William Esper/
William Esper
Legal Assistant and PTAB Coordinator
Finnegan, Henderson, Farabow,
Garrett & Dunner, LLP